Antihypertensive treatment

PreclinicalSmall molecule

UUniversity of Alabama at Birmingham

Antihypertensive treatment is one of 71 small molecule programs targeting Mortality. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MortalityActive, not recruiting

PreeclampsiaActive, not recruiting

MortalityPreclinical

Active, not recruiting

PreeclampsiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Mortality

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

10 2

Lovenox

Sanofi

Approved

1 3

Aldactone

Pfizer

Approved

1 4

Coly-Mycin M

PParkedale

Approved

2 5

Merrem

BB. Braun Medical Inc.

Approved

1 6

Zocor

OOrganon and Co

Approved

1 7

Venofer

AAmerican Regent, Inc.

Approved

1 8

ZINPLAVA

Merck & Co.

Approved

1 9

Mounjaro

Eli Lilly

Phase 3

1 10

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Active, not recruiting

Valid Mesh Conditions

NCT07067632

Q2 2027

N/ARecruiting

Preeclampsia

NCT05676476

Clinical

Trials by Indication[1]

Diastolic Heart Failure1 trial

A Trial of Fimasartan for Early Diastolic Heart Failure

Completed·—·Phase 4·NCT01691118·60 enrolled

Preeclampsia1 trial

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.

Recruiting·UUniversity of Alabama at Birmingham·N/A·NCT05676476·132 enrolled

Valid MeSH Conditions1 trial

Mortality Outcome of Controlled Hypertension in Randomized Controlled or Open-label Study Intentionally Directed Intervention Effect Blood Pressure: A Systematic Review and Meta-Analysis

Active, not recruiting·DDejthidaNathaphong··NCT07067632·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Antihypertensive treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antihypertensive treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antihypertensive treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Alabama at Birmingham

Antihypertensive treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Diastolic Heart Failure1 trial

Preeclampsia1 trial

Valid MeSH Conditions1 trial

References

Drug Info

Quick Facts

Related News